Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables - Other: 2022-2024

Historic Receivables - Other for Corvus Pharmaceuticals (CRVS) over the last 2 years, with Sep 2024 value amounting to $70,000.

  • Corvus Pharmaceuticals' Receivables - Other was N/A to $70,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $70,000, marking a year-over-year change of. This contributed to the annual value of $26,000 for FY2023, which is 95.58% down from last year.
  • Corvus Pharmaceuticals' Receivables - Other amounted to $70,000 in Q3 2024, which was up 100.00% from $35,000 recorded in Q2 2024.
  • Corvus Pharmaceuticals' Receivables - Other's 5-year high stood at $588,000 during Q4 2022, with a 5-year trough of $26,000 in Q4 2023.
  • Moreover, its 3-year median value for Receivables - Other was $373,000 (2022), whereas its average is $269,222.
  • Examining YoY changes over the last 5 years, Corvus Pharmaceuticals' Receivables - Other showed a top increase of 15.01% in 2023 and a maximum decrease of 95.58% in 2023.
  • Corvus Pharmaceuticals' Receivables - Other (Quarterly) stood at $588,000 in 2022, then slumped by 95.58% to $26,000 in 2023, then tumbled by 93.94% to $70,000 in 2024.
  • Its Receivables - Other stands at $70,000 for Q3 2024, versus $35,000 for Q2 2024 and $26,000 for Q1 2024.